Geneva, June 4 -- International Clinical Trials Registry received information related to the study (ISRCTN15824224) titled 'Comparison of the effect of iguratimod and hydroxychloroquine in the treatment of primary Sjogren's syndrome' on May 15.
Study Type: Interventional
Study Design:
Single-center interventional double-blind randomized controlled trial (Treatment, Efficacy)
Primary Sponsor: Mianyang Central Hospital
Condition:
Patients with primary Sjogren's syndrome
Musculoskeletal Diseases
Intervention:
The patients were randomly assigned to an iguratimod (IGU) group (n = 30) or a hydroxychloroquine (HCQ) group (n = 30) at a ratio of 1:1. All the patients were allowed to receive <0 mg of prednisone per day and vitamin D and ca...